Skip to main content
. Author manuscript; available in PMC: 2019 Apr 22.
Published in final edited form as: Mol Imaging Biol. 2017 Jun;19(3):421–428. doi: 10.1007/s11307-016-1008-z

Fig. 2.

Fig. 2.

4-[18F]F-Gln uptake reflects molecular response to mutant BRAF therapy in vivo. Representative transverse and coronal a 4-[18F]F-Gln, and b [18F]FDG PET images of COLO-205 xenograft tumor-bearing vehicle or BEZ-235/PLX-4720-treated mice; tumors are denoted by white arrows. PET quantification of tissue %ID/g revealed a significant difference between vehicle and PLX-4720-single-agent and BEZ-235/PLX-4720 combination-treated xenografts only for c 4-[18F]F-Gln while d [18F]FDG PET was significantly reduced non-specifically in all the treated cohorts. PLX-4720 exposure led to decreased pERK levels in Colo- 205 xenografts while BEZ-235 exposure led to decreased pAKT. e Similarly, combination treatment led to decreases in both pERK and pAKT levels. d Changes in C0L0–205 tumor volume by the tenth day of treatment (N ≥ 8 for all cohorts), shown as percent change from day one baseline, revealed a significant reduction in size from vehicle-treated mice for PLX-470 and BEZ- 235/PLX-4720-treated tumors (p = 0.0001 and p = 0.0005, respectively).